tradingkey.logo

MiNK Therapeutics tumbles after $50 mln stock offering filing

ReutersJul 15, 2025 11:48 AM

Shares of MiNK Therapeutics INKT.O tumble 23.7% premarket to $31 on equity raise plans

New York City-based firm files up to $50 mln ATM (at-the-market) equity sales program to be handled by B. Riley Secs

Co expects to use net offering proceeds for working capital, and other general purposes including R&D expenditures, preclinical and clinical development and commercialization of its product candidates, among other purposes

INKT shares on Fri surged 730% to close at $64.17 after co said its experimental allogeneic cell therapy, agenT-797, showcased complete remission in a patient with advanced testicular cancer, as published in Oncogene

Mid-stage data expected in upcoming months and study is enrolling patients, co said

Shares retreated ~37% on Mon, finishing at $40.61

Co has ~4 mln shares outstanding for $162 mln market cap through Mon, and ~1 mln shares of public float

2 brokerages rate INKT "buy" and 1 rates "hold". There are just 2 PTs on the stock: B. Riley ($7) and H.C. Wainwright ($35) - LSEG data

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI